MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


TOP NEWS: US sends drugmakers initial offers in Medicare price talks

ALN

The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

The move comes as President Joe Biden pushes to rein in health care costs ahead of November’s election.

The negotiation program came on the back of Biden’s landmark Inflation Reduction Act, a major package of energy transition policy and social reforms.

This allowed Medicare, the federal health insurance for seniors, to start negotiating drug costs  a first in its nearly 60-year existence.

‘This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set,’ the White House said in a statement on Thursday.

It did not reveal how much it offered for each drug.

A Johnson & Johnson spokesperson told AFP the company has received an initial price from the government but said it was ‘respecting the confidential nature of the process.’

Last October, major drugmakers behind 10 selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.

But pharmaceutical companies have pushed back against the initiative, earlier saying that they came on board as they had no choice.

While the US government is initially limited to picking 10 drugs for price talks, it can expand the program in subsequent years.

The drugs include Farxiga by AstraZeneca PLC used against diabetes, Entresto by Novartis AG to treat heart failure, as well as anticoagulant Eliquis  used by millions of Medicare beneficiaries.

According to the White House, nine million seniors on Medicare were prescribed the 10 drugs in 2022, spending some $3.4 billion out-of-pocket that year.

The statement also took aim at Big Pharma, which the White House said ‘charged Americans two to three times more’ than in other countries, even when accounting for rebates and discounts.

Biden, who is campaigning for reelection with a large focus on easing voters’ financial burdens, said in a separate statement: ‘My administration won’t stop fighting to lower health care costs for seniors and families.’

New negotiated prices for the 10 prescription drugs are set to be announced later this year.

Medicare is expected to negotiate prices for up to 60 drugs over the next four years, and up to an additional 20 drugs each year after that.

Several companies have taken legal action challenging the provisions.

source: AFP

Copyright 2024 Alliance News Ltd. All Rights Reserved.